These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 36285546)
21. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. Gabriel L; Beriot-Mathiot A J Hosp Infect; 2014 Sep; 88(1):12-21. PubMed ID: 24996516 [TBL] [Abstract][Full Text] [Related]
22. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure. Johnson SW; Brown SV; Priest DH Clin Infect Dis; 2020 Aug; 71(5):1133-1139. PubMed ID: 31560051 [TBL] [Abstract][Full Text] [Related]
23. Modeling the potential impact of administering vaccines against Clostridioides difficile infection to individuals in healthcare facilities. Toth DJA; Keegan LT; Samore MH; Khader K; O'Hagan JJ; Yu H; Quintana A; Swerdlow DL Vaccine; 2020 Aug; 38(37):5927-5932. PubMed ID: 32703744 [TBL] [Abstract][Full Text] [Related]
24. The use of laboratory-identified event surveillance to classify adverse outcomes due to Shen Y; Ellison J; Leal J; Bush KR; Chandran AU; Fathima S; Conly JM Infect Control Hosp Epidemiol; 2021 May; 42(5):557-564. PubMed ID: 33222722 [TBL] [Abstract][Full Text] [Related]
25. The Economic Burden of Braae UC; Møller FT; Ibsen R; Ethelberg S; Kjellberg J; Mølbak K Front Public Health; 2020; 8():562957. PubMed ID: 33324595 [No Abstract] [Full Text] [Related]
26. Burden of Clostridium difficile on the healthcare system. Dubberke ER; Olsen MA Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S88-92. PubMed ID: 22752870 [TBL] [Abstract][Full Text] [Related]
27. Characterizing Magro M; Rosenberg J; Epson E Infect Control Hosp Epidemiol; 2021 Mar; 42(3):292-297. PubMed ID: 32993820 [TBL] [Abstract][Full Text] [Related]
28. Economic Burden of Clostridioides difficile Infection in European Countries. Reigadas E; Vázquez-Cuesta S; Bouza E Adv Exp Med Biol; 2024; 1435():1-12. PubMed ID: 38175468 [TBL] [Abstract][Full Text] [Related]
29. Health care resource utilization and costs of recurrent Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939 [No Abstract] [Full Text] [Related]
30. Inpatient Expenditures Attributable to Hospital-Onset Clostridium difficile Infection: A Nationwide Case-Control Study in Japan. Fukuda H; Yano T; Shimono N Pharmacoeconomics; 2018 Nov; 36(11):1367-1376. PubMed ID: 30022364 [TBL] [Abstract][Full Text] [Related]
31. Assessing risk factors, mortality, and healthcare utilization associated with Clostridioides difficile infection in four Latin American countries. Yu H; Flaster N; Casanello AL; Curcio D Braz J Infect Dis; 2021; 25(1):101040. PubMed ID: 33290727 [TBL] [Abstract][Full Text] [Related]
32. The economic burden of Duhalde L; Lurienne L; Wingen-Heimann SM; Guillou L; Buffet R; Bandinelli PA Infect Control Hosp Epidemiol; 2020 Jul; 41(7):813-819. PubMed ID: 32408912 [TBL] [Abstract][Full Text] [Related]
33. Healthcare facility-onset, healthcare facility-associated Evans CT; Fitzpatrick M; Ramanathan S; Kralovic SM; Burns SP; Goldstein B; Smith B; Gerding DN; Johnson S J Spinal Cord Med; 2020 Sep; 43(5):642-652. PubMed ID: 31663843 [No Abstract] [Full Text] [Related]
34. Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Olsen MA; Keller MR; Stwalley D; Yu H; Dubberke ER Open Forum Infect Dis; 2023 Aug; 10(8):ofad313. PubMed ID: 37547851 [TBL] [Abstract][Full Text] [Related]
35. The economic burden of Clostridium difficile. McGlone SM; Bailey RR; Zimmer SM; Popovich MJ; Tian Y; Ufberg P; Muder RR; Lee BY Clin Microbiol Infect; 2012 Mar; 18(3):282-9. PubMed ID: 21668576 [TBL] [Abstract][Full Text] [Related]
36. Impact of the COVID-19 pandemic on the incidence of healthcare facility-onset Clostridioides difficile infection in hospitalized patients with sepsis: Interrupted time series analysis using Japanese Diagnosis Procedure Combination data. Endo K; Mizuno K; Takeuchi M; Kawakami K Anaerobe; 2023 Feb; 79():102693. PubMed ID: 36623703 [TBL] [Abstract][Full Text] [Related]
37. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection. Webb BJ; Subramanian A; Lopansri B; Goodman B; Jones PB; Ferraro J; Stenehjem E; Brown SM Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964789 [No Abstract] [Full Text] [Related]
38. Differences in time-to-testing and time-to-isolation between community-onset and hospital-onset Clostridioides difficile cases at a tertiary care VA medical center. Hostler CJ; Bertumen JB; Park LP; Wilkins SB; Woods CW Am J Infect Control; 2020 Oct; 48(10):1148-1151. PubMed ID: 31911067 [TBL] [Abstract][Full Text] [Related]
39. Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study. Antunes A; Tricotel A; Wilk A; Dombrowski S; Rinta-Kokko H; Andersson FL; Ghosh S BMC Infect Dis; 2024 May; 24(1):548. PubMed ID: 38822244 [TBL] [Abstract][Full Text] [Related]
40. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. Yu H; Baser O; Wang L BMC Geriatr; 2016 Nov; 16(1):193. PubMed ID: 27884118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]